Abstract 176P
Background
Neuroendocrine tumors are tumors that originate from endocrine cells in various organs, and show very heterogeneous characteristics, and their incidence is gradually increasing. Among them, neuroendocrine tumors originating from the pancreas are divided into functional tumors and non-functional tumors according to the secretion function of hormones. Therefore, we aimed to find protein biomarkers for diagnosis and differential diagnosis of pancreatic neuroendocrine tumor (PNET) through proteomic analysis of human blood.
Methods
A total of 60 human plasma samples were collected from 17 PNETs, 23 PDACs and 20 healthy donors, and liquid chromatography-mass spectrometry (LC-MS) proteomics analysis was performed on 60 human raw data. Identification and label-free quantification were performed through the swissprot protein sequence database. To investigate the function of CD163 among these three biomarker candidates, CD163-expressing cell lines were generated and 3 kinds of experiments were conducted. Additionally, to investigate the correlation between CD163 expression and cells, CBC analysis was performed by collecting blood and tumor tissues from mice transplanted with PNET and PDAC cell lines.
Results
An average of 549 protein lists were secured through LC-MS proteomics analysis using 60 samples, proteomes increased or decreased with disease were analyzed and classified through quantitative evaluation, and ACTR3, CD163, and LECT2 increased in PNET were selected as candidates for diagnostic biomarkers. The diagnostic AUC to differentiate PNET from HD was 0.971 for CD163 and the differential AUC to distinguish between PNET and PDAC was 0.870 for CD163. Additionally, CD163 was confirmed in the blood and tumor tissues of mice transplanted with PNET and PDAC cell lines, and significant results were obtained in PNET. Among the three biomarkers, CD163 was knocked-in to the PNET cell line to confirm the effect of CD163 on PNET.
Conclusions
These three markers will be used to identify molecular biological mechanisms for the generation and progression of PNET, and to study their function as markers that can simultaneously predict diagnosis and treatment response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract